These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

107 related items for PubMed ID: 164312

  • 1. Effects of clofibrate and a fat-modified diet on serum lipids.
    Brown HB, Lewis LA, Page IH.
    Clin Pharmacol Ther; 1975 Feb; 17(2):171-8. PubMed ID: 164312
    [Abstract] [Full Text] [Related]

  • 2. Effect of vitamin E on serum cholesterol and triglycerides in hyperlipidemic patients treated with diet and clofibrate.
    Leonhardt ET.
    Am J Clin Nutr; 1978 Jan; 31(1):100-5. PubMed ID: 202160
    [Abstract] [Full Text] [Related]

  • 3. [Effect of a clofibrate-inositol nicotinate combination on lipids and lipoproteins in primary hyperlipoproteinemia of types IIa, IV and V].
    Hutt V, Wechsler JG, Klör HU, Ditschuneit H.
    Arzneimittelforschung; 1983 Jan; 33(5):776-9. PubMed ID: 6683558
    [Abstract] [Full Text] [Related]

  • 4. Polyunsaturated meat and dairy products in fat-modified food patterns for hyperlipidemia.
    Brown HB, deWolfe VG, Naito HK, Harper WJ, Palmquist DL.
    J Am Diet Assoc; 1976 Sep; 69(3):235-42. PubMed ID: 181413
    [Abstract] [Full Text] [Related]

  • 5. Pronounced lipoprotein lipid reduction obtained by combined lipid-lowering treatment in patients with atherosclerotic disease.
    Vessby B, Lithell H, Gustafsson IB, Borberg J.
    Atherosclerosis; 1979 Aug; 33(4):457-77. PubMed ID: 228684
    [Abstract] [Full Text] [Related]

  • 6. Clofibrate-induced low density liporotein elevation. Therapeutic implications and treatment by colestipol resin.
    Rose HG, Haft GK, Juliano J.
    Atherosclerosis; 1976 Aug; 23(3):413-27. PubMed ID: 178325
    [Abstract] [Full Text] [Related]

  • 7. Cholestyramine, clofibrate and nicotinic acid as single or combined treatment of type IIa and IIb hyperlipoproteinaemia.
    Orö L, Olsson AG, Rössner S, Carlson LA.
    Postgrad Med J; 1975 Aug; 51(8):suppl 76-81. PubMed ID: 215986
    [Abstract] [Full Text] [Related]

  • 8. Dose-response effect of single and combined clofibrate (Atromidin) and niceritrol (Perycit) treatment on serum lipids and lipoproteins in type II hyperlipoproteinaemia.
    Olsson AG, Orö L, Rössner S.
    Atherosclerosis; 1975 Aug; 22(1):91-101. PubMed ID: 1098680
    [Abstract] [Full Text] [Related]

  • 9. Colestipol, clofibrate, cholestyramine and combination therapy in the treatment of familial hyperbetalipoproteinaemia.
    Stein EA, Heimann KW.
    S Afr Med J; 1975 Jul 19; 49(31):1252-6. PubMed ID: 168650
    [Abstract] [Full Text] [Related]

  • 10. Effect of dietary treatment on the lipid, lipoprotein and fatty acid compositions in type IV familial hypertriglyceridemia.
    Agheli N, Cloarec M, Jacotot B.
    Ann Nutr Metab; 1991 Jul 19; 35(5):261-73. PubMed ID: 1776822
    [Abstract] [Full Text] [Related]

  • 11. Gemfibrozil: effect on serum lipids, lipoproteins, postheparin plasma lipase activities and glucose tolerance in primary hypertriglyceridaemia.
    Nikkilä EA, Ylikahri R, Huttunen JK.
    Proc R Soc Med; 1976 Jul 19; 69 Suppl 2(Suppl 2):58-63. PubMed ID: 190608
    [Abstract] [Full Text] [Related]

  • 12. Hyperlipidemia in coronary heart disease. 3. Evaluation of lipoprotein phenotypes of 156 genetically defined survivors of myocardial infarction.
    Hazzard WR, Goldstein JL, Schrott MG, Motulsky AG, Bierman EL.
    J Clin Invest; 1973 Jul 19; 52(7):1569-77. PubMed ID: 4352458
    [Abstract] [Full Text] [Related]

  • 13. Clofibrate in type II hyperlipoproteinemia.
    Ditzel J, Bang HO.
    Acta Med Scand; 1976 Jul 19; 200(1-2):55-58. PubMed ID: 183462
    [Abstract] [Full Text] [Related]

  • 14. One-year trials with halofenate, clofibrate, and placebo.
    Dujovne CA, Azarnoff DL, Huffman DH, Pentikäinen P, Hurwitz A, Shoeman DW.
    Clin Pharmacol Ther; 1976 Mar 19; 19(3):352-9. PubMed ID: 177242
    [Abstract] [Full Text] [Related]

  • 15. Reduction of plasma lipids, lipoproteins, and apoproteins by dietary fish oils in patients with hypertriglyceridemia.
    Phillipson BE, Rothrock DW, Connor WE, Harris WS, Illingworth DR.
    N Engl J Med; 1985 May 09; 312(19):1210-6. PubMed ID: 3990714
    [Abstract] [Full Text] [Related]

  • 16. Replacement of carbohydrate by protein in a conventional-fat diet reduces cholesterol and triglyceride concentrations in healthy normolipidemic subjects.
    Wolfe BM, Piché LA.
    Clin Invest Med; 1999 Aug 09; 22(4):140-8. PubMed ID: 10497712
    [Abstract] [Full Text] [Related]

  • 17. Low-fat diet versus low-carbohydrate diet in the treatment of type IV hyperlipoproteinaemia.
    Sommariva D, Scotti L, Fasoli A.
    Atherosclerosis; 1978 Jan 09; 29(1):43-51. PubMed ID: 204316
    [Abstract] [Full Text] [Related]

  • 18. [Comparative studies on the cholesterol and triglyceride-lowering effect of alpha-methylthyroxine (Skleronorm) and clofibrate (Regelan) in hyperlipoproteinemias of type IIa/b and IV].
    Jantke J, Schwartzkopff W, Zschiedrich M.
    Verh Dtsch Ges Inn Med; 1978 Jan 09; 83():392-5. PubMed ID: 206057
    [No Abstract] [Full Text] [Related]

  • 19. [Treatment of primary hyperlipoproteinemias of type IIB and IV with butylbiguanide and clofibrate (author's transl)].
    Koschinsky T, Gries FA, Schwandt P, Weisweiler P, Hansen W, Nijssen J, Beckmann R.
    MMW Munch Med Wochenschr; 1977 May 20; 119(20):701-4. PubMed ID: 195201
    [Abstract] [Full Text] [Related]

  • 20. Hypolipidemic effect of tibric acid. A comparison with clofibrate and placebo in type IV hyperlipoproteinemia.
    Bielmann P, Brun D, Moorjani S, Gagnon MA, Tétreault L, Lupien PJ.
    Int J Clin Pharmacol Biopharm; 1977 Apr 20; 15(4):166-71. PubMed ID: 192685
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.